# Skye Bioscience

Skye Bioscience is an Asset Manager based in San Diego, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** San Diego, CA, United States
- **Assets under management:** Undisclosed
- **Website:** skyebioscience.com
- **LinkedIn:** https://www.linkedin.com/company/emeraldbioscience

## Regulatory record

- **Reports private funds:** No

## About

We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.

## Sectors

- Biotechnology
- Obesity & Metabolic Disease

## People

- Punit Dhillon — President and Chief Executive Officer
- Tu Diep — not specified on website
- Christopher Twitty — not specified on website
- Puneet S. Arora — Chief Medical Officer

## Questions

### Who runs investment decisions at Skye Bioscience?

Punit Dhillon has served as President and CEO since 2020. The firm's pipeline strategy and clinical development are led by a team including Chief Medical Officer Dr. Puneet Arora and senior scientists. Board members such as Andy Schwab (5AM Ventures) and Dr. Annalisa Jenkins provide additional governance (per the firm).

### How does Skye Bioscience source proprietary drug candidates?

Skye licenses or acquires early-stage assets, most notably the peripheral CB1 antibody nimacimab. Dhillon led that acquisition alongside attracting specialist life science investors. The firm also leverages board and advisor networks for pipeline opportunities (per the firm).

### Does Skye Bioscience participate in fund commitments or only direct drug development?

Skye operates as a drug developer, not an investment vehicle. It does not make third-party fund commitments. The firm deploys capital directly into R&D and clinical trials for its own pipeline.

### What investment stages does Skye Bioscience typically target?

Skye focuses on clinical-stage development, advancing assets from initial clinical proof-of-concept through Phase 2 and beyond. Its lead program, nimacimab, has completed a Phase 2a trial (per the firm, October 2025).

## Related profiles

- [Best Lawyers](https://altss.com/profile/best-lawyers)
- [Topgolf Callaway Brands Corp.](https://altss.com/profile/topgolf-callaway-brands-corp)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/skye-bioscience

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology